Table 4.

Adjusted comparison of acute respiratory-related hospitalisation in patients newly treated with antifibrotic drugs (multivariate analyses)

	HR	95% CI	p-value
Treatment
Pirfenidone	1.00	–	–
Nintedanib	1.32	1.01–1.73	0.04
Age at treatment initiation	0.99	0.98–1.01	0.41
Sex
Male	1.00	–	–
Female	0.98	0.74–1.30	0.90
Year of antifibrotic treatment initiation
2015	1.00	–	–
2016	0.70	0.53–0.91	0.01
Time from IPF diagnosis to treatment initiation	1.01	1.00–1.01	0.02
Number of acute respiratory-related hospital admissions during the year prior to treatment initiation
0	1.00	–	–
1	1.42	1.10–1.84	0.01
2 or more	2.27	1.64–3.15	< 0.01
Number of outpatient visits to a hospital physician during the year prior to treatment initiation
0	1.00	–	–
1 or 2	1.08	0.68–1.72	0.75
3 or 4	0.99	0.61–1.60	0.97
5 or more	1.11	0.69–1.78	0.66
Charlson comorbidity score
1–2	1.00	–	–
3–4	1.33	0.91–1.94	0.14
5 or more	1.35	0.87–2.09	0.18
Use of supplemental oxygen at baseline
Yes	2.02	1.57–2.60	< 0.01

CI confidence interval, HR hazard ratio, IPF idiopathic pulmonary fibrosis